Evaxion Biotech A/S

Evaxion Biotech A/S engages in the discovery and development of novel immunotherapies for cancer and infectious diseases. It uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evaxion Biotech reports positive Q2 results and compliance plans

Evaxion Biotech A/S showcased strong performance in Phase II immune data.
The company is strategically positioned with a focused business model.
Challenges like compliance and financial impacts are being addressed proactively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its third quarter 2022 financial results and provided an operational and business update.

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.

Evaxion CEO comments on strategic focus

COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd.

Evaxion welcomes Per Norlén as new CEO.

Athersys

Medigus Ltd Sponsored

High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Cepton

Which penny stocks are on your buy list right now? The post Good Penny Stocks to Add to Your Buy List?

Good Penny Stocks to Add to Your Buy List? 3 to Watch

Today's price action (prior to the Federal Reserve's rate hike decision at least) has been broadly positive. But for investors in Evaxion Biotech (NASDAQ: EVAX ), it's been a heck of a day.

Why Is Evaxion Biotech (EVAX) Stock Up Today?

COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01, the Company's personalized cancer therapy for the treatment of melanoma.

Important Milestone Reached for Evaxion Biotech's EVX-01 Personalized Cancer Therapy

COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for the development of a gonorrhea lead vaccine candidate.

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Evaxion Biotech A/S (EVAX) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Corey Davis - Managing Director, Investor Relations, LifeSci Advisors Lars Wegner - President and CEO Bo Karmark - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good morning, and welcome to the Evaxion Biotech Second Quarter 2022 Earnings Call. All participants will be in a listen-only mode.

Evaxion Biotech A/S (EVAX) CEO Lars Wegner on Q2 2022 Results - Earnings Call Transcript

COPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business update.

Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced the following executive management changes. Lars Staal Wegner has decided to resign as the Company's Chief Executive Officer (CEO). Dr. Wegner will remain with the Company in an advisory role to the Company's new CEO and Board of Directors.

Evaxion Biotech A/S Announces Executive Management Changes

COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT.

Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the Company has identified Gonorrhea as its second bacterial target for treatment with the Company's EVX-B2 vaccine product candidate.

Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

Evaxion Biotech A/S (NASDAQ: EVAX) has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022. We currently have two product candidates in the DNA technology platform, EVX-02, and EVX-03.

Evaxion Biotech To Test EVX-03 DNA Vaccine For Non-Small Cell Lung Cancer

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned regulatory filing in H2 2022.

Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

Evaxion Biotech AS Sponsored ADR (EVAX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that it has entered into a committed equity purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), for the issuance and sale, from time to time, of up to $40 million of its American Depositary Shares (the “ADSs”), each of which represents one ordinary share, DKK 1 nominal value, of the Company (the “Ordinary Shares”).

Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

Evaxion Biotech A/S (EVAX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Corey Davis – LifeSci Advisors Lars Wegner – Chief Executive Officer Jesper Nyegaard Nissen – Interim Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenheimer Ahu Demir – Ladenburg Thomas Flaten – Lake Street Operator Greetings, and welcome to the Evaxion Biotech First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Evaxion Biotech A/S' (EVAX) CEO Lars Wegner on Q1 2022 Results - Earnings Call Transcript

COPENHAGEN, Denmark, May 11, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today the first quarter 2022 financial results and provided an operational update.

Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

Clover Health Investments

Mullen Automotive

Penny stocks to watch this week. The post Good Penny Stocks To Buy Now?

Good Penny Stocks To Buy Now? 4 For Your May Watch List

COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma.

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial results on May 11 at 8.30 a.m. EDT.

Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

Personalis Inc

MENLO PARK, Calif. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion's personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion's proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with

News for Evaxion Biotech A/S Stock (EVAX)